Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07378579 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001
A Phase 1 study, sponsored by Alumis.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT07378579 is a Phase 1 study that has completed, run by Alumis. The registered enrollment target is 52 participants.
The verdict
NCT07378579, a Phase 1 study, has completed, sponsored by Alumis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants,
Interventions
- DRUG Placebo
- DRUG ESK-001
- DRUG Moxifloxacin (400 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2024-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07378579
The ClinicalTrials.gov registry entry for NCT07378579 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07378579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07378579 about?
NCT07378579 is a clinical study titled "An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001". This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants,
What is the current status of trial NCT07378579?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2024-06-21. Estimated completion is 2024-08-31.
What interventions are being tested in trial NCT07378579?
The interventions under investigation include: Placebo (DRUG), ESK-001 (DRUG), Moxifloxacin (400 mg) (DRUG).
Who is sponsoring clinical trial NCT07378579?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.